

1 **Exclusion tests in Unilateral Primary Aldosteronism**
2 **(ExcluPA) Study**

3 **Subtitle: A systematic review and meta-analysis**

4
5 Author names: Rui Zhu, MD, PhD^{1,2*}; Tungalagtamir Shagjaa, MD^{1,3*}; Giacomo
6 Rossitto, MD, PhD^{1,4}; Brasilina Caroccia, PhD¹; Teresa Maria Seccia, MD, PhD¹;
7 Dario Gregori, MA, PhD⁵; Gian Paolo Rossi, MD¹
8

9 Affiliation:

10 ¹ Internal & Emergency Medicine Unit, Department of Medicine – DIMED, University
11 of Padua, Padua, Italy;

12 ² Department of Endocrinology, Sichuan Academy of Medical Sciences & Sichuan
13 Provincial People's Hospital, Chengdu, China

14 ³Department of Neurology, Mongolian National University of Medical Sciences,
15 Ulaanbaatar, Mongolia;

16 ⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow
17 UK;

18 ⁵ Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
19 Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
20

21 ORCID number: 0000-0002-7963-0931 (G. P. Rossi)
22

23 *These authors have equally contributed.
24

25 Correspondence and reprint request:

26 Prof. Gian Paolo Rossi, MD, FACC, FAHA

27 Dipartimento di Medicina -DIMED

28 Unità Complessa di Medicina d'Urgenza e Centro Regionale Specializzato per i
29 disordini della pressione

30 Università di Padova,

31 via Giustiniani, 2, 35122 Padova, Italy.

32 E-mail: gianpaolo.rossi@unipd.it
33

34 **Supplemental Literature Search**

35 **Table S1.** Gold and Golden Criteria for the Diagnosis of Unilateral Aldosteronism

36 **Table S2.** Quantitative Scoring Method for the Assessment of Bias Risk

37 **Table S3.** Excluded studies and criteria for exclusion

38 **Table S4.** Quantitative Scoring for the Quality of Each Single Study

39 **Table S5.** Additional Patients' Characteristics

40 **Table S6.** Meta-regression of the Aldosterone-to-renin Ratio

41 **Table S7.** Meta-regression of the Captopril Challenge Test

42 **Table S8.** Meta-regression of the Saline Infusion Test

43 **Figure S1.** PRISMA Flow Chart

44 **Figure S2.** Mean Average of Quantitative Scoring of the ARR, CCT, and SIT

45 **Figure S3.** Sensitivity Analysis of the Aldosterone-to-renin Ratio

46 **Figure S4.** Sensitivity Analysis of the Captopril Challenge Test

47 **Figure S5.** Sensitivity Analysis of the Saline Infusion Test

48 **Figure S6.** Funnel Plot Assessing Publication Bias of the ARR, CCT, and SIT

49 **Supplemental Literature Search**

50 Using terms and boolean operators in combination, we conducted a systematic search of relevant articles
51 from PubMed, EMBASE, Web of Science, and Cochrane Library databases on the diagnostic
52 performance of the screening and exclusion tests of human PA published from January 1st, 1970 to
53 December 31st, 2021. The references of published articles were also screened to identify additional
54 relevant studies.

55

56 **PubMed**

57 Search: (((("Hyperaldosteronism"[Mesh]) OR (((((((entry terms: Aldosteronism[Title/Abstract]) OR
58 (Conn Syndrome[Title/Abstract])) OR (Syndrome, Conn[Title/Abstract])) OR (Primary
59 Hyperaldosteronism[Title/Abstract])) OR (Hyperaldosteronism, Primary[Title/Abstract])) OR (Conn's
60 Syndrome[Title/Abstract * [Title/Abstract]) OR predictive value of tests[MeSH Term] OR
61 accuracy*[Title/Abstract])) AND (("1970/01/01"[Date - Publication] : "2021/12/31"[Date - Publication]))

62 Filters: English

63 Items found: 852

64

65 **EMBASE**

No.	Query	Results
#1	'hyperaldosteronism'/exp	15678
#2	'aldosteronism':ab,ti OR 'conn syndrome':ab,ti OR 'syndrome, conn':ab,ti OR 'primary hyperaldosteronism':ab,ti OR 'hyperaldosteronism, primary':ab,ti OR 'conns syndrome':ab,ti	8025
#3	#1 OR #2	16542
#4	'sensitivity and specificity'/exp	418850
#5	'predictive value'/exp	207949
#6	'sensitiv*':ab,ti OR 'accuracy*':ab,ti	2361143
#7	#4 OR #5 OR #6	2583822
#8	#3 AND #7	1635
#9	#3 AND #7 AND [english]/lim AND [1970-2021]/py	1480
#10	#3 AND #7 AND [english]/lim AND [1970-2021]/py AND [humans]/lim	1303

Items found: 1303

66

67 **Web of Science**

# 1	TS= (Hyperaldosteronism or Aldosteronism or Conn Syndrome or Syndrome, Conn or Primary Hyperaldosteronism or Hyperaldosteronism, Primary or Conn's Syndrome or Conns Syndrome or Syndrome, Conn's) Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR- EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED	7109
# 2	TS= ((sensitivity and specificity) or predictive value of test or (predictive and value*) or sensitiv* or accuracy*) Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR- EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED	3820274
# 3	#1 AND #2 Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR-	854

# 4	EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED #3 Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR- EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED Timespan=1970-01-01 to 2021-12-31	850
# 5	#5 AND #1 Refined by: LANGUAGES: (ENGLISH) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=1970-01-01 to 2021-12-31	818

Items found: 818

68

69 **Cochrane Library**

ID	Search	Hits
#1	MeSH descriptor: [Hyperaldosteronism] explode all trees	67
#2	(Aldosteronism):ti,ab,kw OR (Conn Syndrome):ti,ab,kw OR (Syndrome, Conn):ti,ab,kw OR (Primary Hyperaldosteronism):ti,ab,kw OR (Hyperaldosteronism, Primary):ti,ab,kw OR (Conn's Syndrome):ti,ab,kw OR (Conns Syndrome):ti,ab,kw OR (Syndrome, Conn's):ti,ab,kw	157
#3	#1 OR #2	177
#4	MeSH descriptor: [Sensitivity and Specificity] explode all trees	15311
#5	MeSH descriptor: [Predictive Value of Tests] explode all trees	6937
#6	(sensitivity):ti,ab,kw OR (accuracy):ti,ab,kw	86299
#7	#4 OR #5 OR #6	91652
#8	#3 AND #7	37
#9	#3 AND #7 with Publication Year from 1970 to 2021, in Trials	37

Items found: 37

70

71 The final literature search was performed on 9th February 2021 (all database, by RZ)

72

73 **Total items found: 3010**

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 **eTable 1.** Gold and Golden Criteria for the Diagnosis of Unilateral Primary Aldosteronism

89

Gold:
“Four corners” criteria
1. Excessive aldosterone production
2. Lateralization of aldosterone secretion at adrenal venous sampling or adrenal scintigraphy
3. Adenoma/hyperplasia demonstration at pathology
4. Correction of biochemical values and fall of blood pressure after adrenalectomy

90

Golden:
1. Excessive aldosterone production
2. Lateralization of aldosterone secretion at adrenal venous sampling or adrenal scintigraphy
3. Positive adrenal imaging

91

92 **Table S2.** Quantitative Scoring Method for the Assessment of Bias Risk

Domain	Item	Score
Study design & patient selection	1. Were the patients enrolled consecutively or randomly, or not?	0 1 2 3 4 5 6 7 8 9 10
	2. Were the patients pre-selected? e.g. patients with positive and negative ARR, or patients with positive ARR?	0 1 2 3 4 5 6 7 8 9 10
Index test	3. Were the cut-off values of ARR, and/or exclusion tests, pre-specified?	0 1 2 3 4 5 6 7 8 9 10
	4. Were the results interpreted with no knowledge of the final diagnosis?	0 1 2 3 4 5 6 7 8 9 10
Reference standard	5. Was the reference standard used to classify uPA appropriately used?	0 1 2 3 4 5 6 7 8 9 10
	6. Were the results interpreted with no knowledge of the index test?	0 1 2 3 4 5 6 7 8 9 10
Flow & timing	7. Did all patients receive the reference standard?	0 1 2 3 4 5 6 7 8 9 10
	8. Did all patients receive the same reference standard?	0 1 2 3 4 5 6 7 8 9 10
	9. Were some patients excluded from the analysis?	0 1 2 3 4 5 6 7 8 9 10
Total		

93 ARR, aldosterone-to-renin ratio; uPA, unilateral primary aldosteronism.

94 **Table S3.** Excluded studies and criteria for exclusion

Study	Exclusion criteria
Adilijiang, M., 2021 (1)	Insufficient data to construct a 2x2 table based on uPA
Ahmed, A., 2014 (2)	Duplicate data
Arteaga, E., 1985 (3)	Exclusion test for PA subtyping
Berge, C., 2015 (4)	Wrong calculation of plasma renin concentration
Burrello, J., 2020 (5)	Duplicate data
Castro, O. L., 2002 (6)	Insufficient data to construct a 2x2 table based on uPA
Fukumoto, T., 2021 (7)	Exclusion test for PA subtyping
Gan, W. J., 2019 (8)	Insufficient data to construct a 2x2 table based on uPA
Guo, Z., 2018 (9)	Duplicate data
Hashimura, H., 2018 (10)	Exclusion test for PA subtyping
Jansen, P. 2014 (11)	Insufficient data to construct a 2x2 table based on uPA
Juutilainen, A. M., 2005 (12)	Case-control study
Kater, C. E., 2004 (13)	Case-control study
Kawashima, J., 2020 (14)	Insufficient data to construct a 2x2 table based on uPA
Kidoguchi, S., 2019 (15)	Insufficient data to construct a 2x2 table based on uPA
Kline, G. A., 2014 (16)	Insufficient data to construct a 2x2 table based on uPA
Kuo, C. C., 2015 (17)	Duplicate data
Li, T. Q., 2019 (18)	Insufficient data to construct a 2x2 table based on uPA
Li, Y. Y., 2016 (19)	Duplicate data
Lin, C., 2020 (20)	Duplicate data
Lyons, D. F., 1983 (21)	Case-control study
Ma, L. Q., 2018 (22)	Duplicate data
Mantero, F., 1990 (23)	Exclusion test for PA subtyping
Montori, V. M., 2001 (24)	Insufficient data to construct a 2x2 table based on uPA
Muratani, H., 1987 (25)	Case-control study
Myśliwiec, J., 2012 (26)	Insufficient data to construct a 2x2 table based on uPA
Nagano, H., 2020 (27)	Exclusion test for PA subtyping
Nanba, K., 2012 (28)	Exclusion test for PA subtyping
Naomi, S., 1987 (29)	Case-control study
Pilz, S., 2019 (30)	Insufficient data to construct a 2x2 table based on uPA
Rossi, E., 2002 (31)	Case-control study
Rossi, G. P., 2007 (32)	Duplicate data
Schirpenbach, C., 2006 (33)	Case-control study
Streeten, D. H., 1982 (34)	Insufficient data to construct a 2x2 table based on uPA
Sun, F., 2021 (35)	Exclusion test for PA subtyping
Tamura, N., 2020 (36)	Insufficient data to construct a 2x2 table based on uPA
Thuzar, M., 2020 (37)	Duplicate data
Wang, K. R., 2020 (38)	Insufficient data to construct a 2x2 table based on uPA
Yamashita, K., 2020 (39)	Exclusion test for PA subtyping
Zhu, K. Y., 2019 (40)	Insufficient data to construct a 2x2 table based on uPA

95 PA, primary aldosteronism; uPA, unilateral primary aldosteronism.

96 **Table S4.** Quantitative Scoring for the Quality of Each Single Study

	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
ARR									
Bernini 2008	7	8	4	5	6	5	3	3	6
Burrello 2016	6	4	10	5	4	4	4	4	5
Ducher 2012	8	4	8	8	5	3	5	7	6
Fries 2020	9	6	2	6	4	2	3	3	4
Giacchetti 2006	3	4	4	5	3	3	3	3	5
Maiolino 2017a	10	9	9	10	9	7	5	7	6
Maiolino 2017b	10	9	9	10	9	7	5	7	6
Okamoto 2018	9	2	10	5	6	5	4	6	3
Vorselaars 2018	9	7	6	6	1	2	5	2	6
Weickert 2009	2	3	1	5	6	2	2	2	5
CCT									
Kim 2016	5	2	9	5	1	5	4	4	8
Maiolino 2017 ^a	10	10	9	10	10	9	5	7	6
Maiolino 2017 ^b	10	10	9	10	10	9	5	7	6
Meng 2018	3	6	9	7	7	8	3	5	9
Okamoto 2019	9	2	10	5	6	5	4	6	3
Rossi 2007	10	10	9	8	8	9	6	7	7
Song 2018	6	3	8	6	4	7	5	5	7
Wu 2009	7	4	9	7	6	5	3	4	8
Wu 2010	8	4	10	7	8	5	4	3	8
SIT									
Fries 2020	9	6	2	6	4	2	3	3	4

Fuss 2021	7	8	4	5	6	5	3	3	6
Meng 2017	3	6	9	6	7	8	3	5	9
Mulatero 2006	5	2	9	5	2	6	2	2	8
Okamoto 2019	9	2	10	5	6	5	4	6	3
Rossi 2007	10	9	8	9	9	9	7	8	7
Song 2017	6	3	8	6	4	7	5	5	7
Stowasser 2018	4	3	9	7	8	7	5	5	5
Vivien 2019	6	6	8	7	7	5	5	4	5
Zhang 2020	3	5	6	7	2	1	1	1	1
FST									
Okamoto 2019	9	2	10	5	6	5	4	6	3
FUT									
Stowasser 2018	4	3	9	7	8	7	5	5	5

97 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test; FST, fludrocortisone suppression test; FUT, furosemide upright test. a and b represent
98 the exploratory and the validation cohort in Maiolino's study, respectively.

99 **Table S5.** Additional Patients' Characteristics

	Setting	Study Design	Wash-out period	Serum K⁺ (mEq/L)	Potassium supplement	Salt intake
Bernini 2008	Single referral center	Retrospective	4w diuretics, 3w others	3.2 (uPA)	Yes	Restricted
Burrello 2016	Single referral center	Prospective	Partly done, 20%	3.6 (PA)	Yes	Liberal
Ducher 2012	Multiple referral centers	Prospective	4w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Liberal
Fries 2020	Multiple referral centers	Prospective	4w MRA/diuretics, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Liberal
Fuss 2021	Single referral center	Prospective	4w MRA, > 1w others, only maintain CCB and/or a-blocker	3.7 (uPA)	Yes	Liberal
Giacchetti 2006	Single referral center	Prospective	4w discontinued, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Kim 2016	Single referral center	Prospective	6w MRA, 4w others, only maintain CCB and/or a-blocker	3.2 (uPA)	Yes	Liberal
Maiolino 2017 ^a	Multiple referral centers	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Maiolino 2017 ^b	Single referral center	Prospective	4w discontinued, only maintain CCB and/or a-blocker	3.3 (uPA)	Yes	Restricted
Meng 2018	Single referral center	Retrospective	6w MRA, 4w diuretics, 2w others, only maintain CCB and/or a-blocker	2.9 (uPA)	Yes	Liberal
Mulatero 2006	Multiple referral centers	Prospective	8w MRA, 6w diuretic, 3w others, only maintain CCB and/or a-blocker	3.7 (PA)	Yes	Liberal

Okamoto 2019	Single referral center	Prospective	Only maintain CCB and/or a-blocker	3.3 (uPA)	N.A.	Restricted
Rossi 2007	Multiple referral centers	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Song 2018	Single referral center	Prospective	4w MRA, 2w others, only maintain CCB and/or a-blocker	3.2 (PA)	Yes	Restricted
Stowasser 2018	Single referral center	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.7 (PA)	N.A.	Liberal
Vivien 2019	Single referral center	Retrospective	6w MRA, 4w diuretics, 2w others, only maintain CCB and/or a-blocker	N.A.	Yes	Liberal
Vorselaars 2018	Single referral center	Prospective	≥ 2w discontinued, only maintain CCB and/or a-blocker	N.A.	Yes	Restricted
Weickert 2009	Single referral center	Prospective	≥ 2w discontinued, only maintain CCB and/or a-blocker	3.3 (uPA)	N.A.	Restricted
Wu 2009	Multiple referral centers	Prospective	2w discontinued, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Wu 2010	Single referral center	Prospective	3w discontinued, only maintain CCB and/or a-blocker	3.7 (uPA)	Yes	Restricted
Zhang 2020	Single referral center	Prospective	4w MRA/diuretics, 2w others, only maintain CCB and/or a-blocker	4.0 (uPA)	Yes	Liberal

100 CCB, calcium channel blocker; MRA, mineralocorticoid receptor antagonist; N.A., not available; PA, primary aldosteronism; uPA, unilateral primary aldosteronism. a and b
101 represent the exploratory and the validation cohort in Maiolino's study, respectively.

Table S6. Meta-regression of the Aldosterone-to-renin Ratio

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	9/1	-0.005	2.151	0.998	1.00 (0.00 - 390.56)
Population (suspected PA or positive ARR)	7/3	-2.357	1.829	0.267	0.09 (0.00 - 15.20)
Cutoff (chosen by ROC or not)	5/5	0.898	1.229	0.506	2.45 (0.08 - 74.50)
Reference (golden or gold)	5/5	0.010	1.299	0.994	1.01 (0.03 - 37.21)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.369	1.249	0.116	0.09 (0.00 - 2.32)
Cutoff (chosen by ROC or not)	5/5	0.882	1.014	0.425	2.41 (0.18 - 32.76)
Reference (golden or gold)	5/5	0.069	1.185	0.956	1.07 (0.05 - 22.55)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.275	0.827	0.033	0.10 (0.01 - 0.78)
Cutoff (chosen by ROC or not)	5/5	0.868	0.972	0.406	2.38 (0.22 - 25.66)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.209	0.766	0.024	0.11 (0.02 - 0.67)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Cutoff (chosen by ROC or not)	5/5	0.722	1.217	0.572	2.06 (0.12 - 36.62)

103 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
104 aldosteronism; RDOR, relative diagnostic odds ratio; ROC, receiving operation characteristic curve;
105 Std. Err., standard error.

Table S7. Meta-regression of the Captopril Challenge Test

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	3/6	-0.151	1.979	0.946	0.86 (0.00 - 4293.95)
Population (suspected PA or positive ARR)	3/6	-0.863	1.591	0.642	0.42 (0.00 - 397.11)
Cutoff (chosen by ROC or not)	2/7	-0.537	2.193	0.829	0.58 (0.00 - 7310.15)
Reference (golden or gold)	3/6	-0.089	1.556	0.960	0.92 (0.00 - 739.01)
Readout variable (ARR or PAC)	6/3	2.405	1.601	0.272	11.07 (0.01 - 10841.02)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	3/6	-0.217	1.103	0.857	0.80 (0.02 - 26.95)
Population (suspected PA or positive ARR)	3/6	-0.912	1.181	0.496	0.40 (0.01 - 17.21)
Cutoff (chosen by ROC or not)	2/7	-0.506	1.815	0.799	0.60 (0.00 - 194.43)
Readout variable (ARR or PAC)	6/3	2.439	1.283	0.153	11.46 (0.19 - 678.66)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-0.756	0.751	0.371	0.47 (0.06 - 3.78)
Cutoff (chosen by ROC or not)	2/7	-0.676	1.482	0.672	0.51 (0.01 - 31.18)
Readout variable (ARR or PAC)	6/3	2.430	1.186	0.110	11.36 (0.42 - 305.70)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-0.911	0.631	0.208	0.4 (0.08 - 2.04)
Readout variable (ARR or PAC)	6/3	2.037	0.771	0.046	7.67 (1.06 - 55.66)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Readout variable (ARR or PAC)	6/3	2.283	0.779	0.026	9.81 (1.46 - 65.93)
(6)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-1.253	0.801	0.169	0.29 (0.04 - 2.03)


107 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
108 aldosteronism; PAC, plasma aldosterone concentration; RDOR, relative diagnostic odds ratio; ROC,
109 receiving operation characteristic curve; Std. Err., standard error.

110 **Table S8.** Meta-regression of the Saline Infusion Test

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.647	0.910	0.528	1.91 (0.11 - 34.63)
Population (suspected PA or pos ARR)	3/7	1.349	1.606	0.463	3.85 (0.02 - 639.78)
Cutoff (chosen by ROC or not)	5/5	-0.205	1.429	0.895	0.81 (0.01 - 76.98)
Reference (golden or gold)	3/7	-0.207	1.286	0.883	0.81 (0.01 - 48.75)
Position (seated or recumbent)	5/5	1.459	0.966	0.228	4.30 (0.20 - 93.05)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.770	0.761	0.369	2.16 (0.26 - 17.84)
Population (suspected PA or positive ARR)	3/7	1.180	1.004	0.305	3.26 (0.20 - 52.88)
Reference (golden or gold)	3/7	-0.190	1.113	0.872	0.83 (0.04 - 18.16)
Position (seated or recumbent)	5/5	1.444	0.723	0.116	4.24 (0.57 - 31.56)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.904	0.645	0.220	2.47 (0.47 - 12.96)
Population (suspected PA or positive ARR)	3/7	1.048	0.632	0.158	2.85 (0.56 - 14.48)
Position (seated or recumbent)	5/5	1.456	0.573	0.052	4.29 (0.98 - 18.72)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/7	1.276	0.743	0.137	3.58 (0.58 - 22.05)
Position (seated or recumbent)	5/5	1.440	0.725	0.094	4.22 (0.72 - 24.88)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Position (seated or recumbent)	5/5	1.082	0.845	0.241	2.95 (0.40 - 21.77)
(6)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/7	0.837	0.918	0.392	2.31 (0.26 - 20.22)

111 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
 112 aldosteronism; RDOR, relative diagnostic odds ratio; ROC, receiving operation characteristic curve;
 113 Std. Err., standard error.


114 **Figure S1. PRISMA Flow Chart**



115

116 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; FST, fludrocortisone suppression test;
 117 FUT, furosemide upright test; PA, primary aldosteronism; PRISMA, The Preferred Reporting Items for
 118 Systematic Reviews and Meta-Analyses; SIT, saline infusion test; uPA, unilateral primary aldosteronism.
 119 The exploratory and the validation phase indicate studies using the golden and gold standard for the
 120 diagnosis of uPA, respectively.


121 **Figure S2.** Mean Average of Quantitative Scoring of the ARR, CCT, and SIT



122 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test. a and b represent the exploratory and the validation cohort in Maiolino's study,
 123 respectively.


124

125 **Figure S3.** Sensitivity Analysis of the Aldosterone-to-renin Ratio (ARR).




126 Meta-analysis estimates, given named study is omitted. a and b represent the exploratory and the validation cohort in Maiolino's study, respectively.

127 **Figure S4.** Sensitivity Analysis of the Captopril Challenge Test (CCT).



128 Meta-analysis estimates, given named study is omitted. a and b represent the exploratory and the validation cohort in Maiolino's study, respectively.


129 **Figure S5.** Sensitivity Analysis of the Saline Infusion Test (SIT).




130 Meta-analysis estimates, given named study is omitted.

131 **Figure S6.** Funnel Plot Assessing Publication Bias of the ARR, CCT, and SIT


A. ARR



B. CCT



C. SIT



132 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test.

133 **REFERENCES**

- 134 1. **Adilijiang M, Luo Q, Wang M, Zhang D, Yao X, Wang G, Zhou K, Li N.**
 135 Minor Change of Plasma Renin Activity during the Saline Infusion Test Provide
 136 an Auxiliary Diagnostic Value for Primary Aldosteronism. *Int. J. Endocrinol.*
 137 2021;2021:5757305.
- 138 2. **Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser**
 139 **M.** Seated saline suppression testing for the diagnosis of primary aldosteronism:
 140 a preliminary study. *J. Clin. Endocrinol. Metab.* 2014;99(8):2745–2753.
- 141 3. **Arteaga E, Klein R, Biglieri EG.** Use of the saline infusion test to diagnose the
 142 cause of primary aldosteronism. *Am. J. Med.* 1985;79(0002–9343; 6):722–728.
- 143 4. **Berge C, Courand PY, Harbaoui B, Paget V, Khettab F, Bricca G, Fauvel JP,**
 144 **Lantelme P.** Decreased plasma prorenin levels in primary aldosteronism:
 145 potential diagnostic implications. *J. Hypertens.* 2015;33(1):118–125.
- 146 5. **Burrello J, Buffolo F, Domenig O, Tetti M, Pecori A, Monticone S, Poglitsch**
 147 **M, Mulatero P.** Renin-Angiotensin-Aldosterone System Triple-A Analysis for
 148 the Screening of Primary Aldosteronism. *Hypertens. (Dallas, Tex. 1979)*
 149 2020;75(1):163–172.
- 150 6. **Castro OL, Yu X, Kem DC.** Diagnostic value of the post-captopril test in
 151 primary aldosteronism. *Hypertension* 2002;39:935–938.
- 152 7. **Fukumoto T, Umakoshi H, Ogata M, Yokomoto-Umakoshi M, Matsuda Y,**
 153 **Motoya M, Nagata H, Nakano Y, Iwahashi N, Kaneko H, Wada N,**
 154 **Miyazawa T, Sakamoto R, Ogawa Y.** Significance of Discordant Results
 155 Between Confirmatory Tests in Diagnosis of Primary Aldosteronism. *J. Clin.*
 156 *Endocrinol. Metab.* 2021;106(2):E866–E874.
- 157 8. **Gan W, Lin W, Ouyang J, Li Y, Chen D, Yao Z, Feng P.** High efficiency of the
 158 aldosterone-to-renin ratio in precisely detecting primary aldosteronism. *J. Hum.*
 159 *Hypertens.* 2019;33(1):57–61.
- 160 9. **Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD,**
 161 **Wolley M, Stowasser M.** Aldosterone LC-MS/MS assay-specific threshold
 162 values in screening and confirmatory testing for primary aldosteronism. *J. Clin.*
 163 *Endocrinol. Metab.* 2018;103(11):3965–3973.
- 164 10. **Hashimura H, Shen J, Fuller PJ, Chee NYN, Doery JCG, Chong W, Choy**
 165 **KW, Gwini SM, Yang J.** Saline suppression test parameters may predict
 166 bilateral subtypes of primary aldosteronism. *Clin. Endocrinol. (Oxf).*
 167 2018;89(3):308–313.
- 168 11. **Jansen PM, Van Den Born BJH, Frenkel WJ, De Bruijne ELE, Deinum J,**
 169 **Kerstens MN, Smulders YM, Woittiez AJ, Wijbenga JAM, Zietse R, Danser**
 170 **AHJ, Van Den Meiracker AH.** Test characteristics of the aldosterone-to-renin
 171 ratio as a screening test for primary aldosteronism. *J. Hypertens.*
 172 2014;32(1):115–126.
- 173 12. **Juutilainen AM, Voutilainen ET, Mykkänen L, Niskanen L.** Plasma
 174 aldosterone to renin ratio predicts treatment response in primary aldosteronism:
 175 is volume loading needed? *Blood Press.* 2005;14(4):245–250.

- 176 13. **Kater CE, Biglieri EG.** The syndromes of low-renin hypertension: “separating
177 the wheat from the chaff.” *Arq. Bras. Endocrinol. Metabol.* 2004;48(5):674–681.
- 178 14. **Kawashima J, Araki E, Naruse M, Kurihara I, Takahashi K, Tamura K,**
179 **Kobayashi H, Okamura S, Miyauchi S, Yamamoto K, Izawa S, Suzuki T,**
180 **Tanabe A.** Baseline plasma aldosterone level and renin activity allowing
181 omission of confirmatory testing in primary aldosteronism. *J. Clin. Endocrinol.*
182 *Metab.* 2020;105(5):dgaa117.
- 183 15. **Kidoguchi S, Sugano N, Hayashi-Ishikawa N, Morisawa N, Tokudome G,**
184 **Yokoo T.** The characteristics of captopril challenge test-positive patients using
185 various criteria. *J. Renin. Angiotensin. Aldosterone. Syst.*
186 2019;20(3):1470320319870891.
- 187 16. **Kline GA, Pasieka JL, Harvey A, So B, Dias VC.** High-probability features of
188 primary aldosteronism may obviate the need for confirmatory testing without
189 increasing false-positive diagnoses. *J. Clin. Hypertens. (Greenwich).*
190 2014;16(7):488–496.
- 191 17. **Kuo CC, Balakrishnan P, Hsein YC, Wu VC, Chueh SCJ, Chen YM, Wu**
192 **KD, Wang MJ, Lin YH, Ho YL, Chang HW, Lin LY, Hu FC, Liu KL, Wang**
193 **SM, Huang KH, Chang CC, Lu CC, Liao SC, Yen RF, Lin WC, Hsieh B Sen.**
194 The value of losartan suppression test in the confirmatory diagnosis of primary
195 aldosteronism in patients over 50 years old. *J. Renin. Angiotensin. Aldosterone.*
196 *Syst.* 2015;16(3):587–598.
- 197 18. **Li T, Ma Y, Zhang Y, Liu Y, Fu T, Zhang R, Kang K, Yang Y, Wang L, Jiang**
198 **Y, Lu Y.** Feasibility of Screening Primary Aldosteronism by Aldosterone-to-
199 Direct Renin Concentration Ratio Derived from Chemiluminescent
200 Immunoassay Measurement: Diagnostic Accuracy and Cutoff Value. *Int. J.*
201 *Hypertens.* 2019;2019:2195796.
- 202 19. **Li Y, Liu Y, Li J, Wang X, Yu Y.** Sodium Infusion Test for Diagnosis of Primary
203 Aldosteronism in Chinese Population. *J. Clin. Endocrinol. Metab.*
204 2016;101(1):89–95.
- 205 20. **Lin C, Yang J, Fuller PJ, Jing H, Song Y, He W, Du Z, Luo T, Cheng Q, Yang**
206 **S, Wang H, Li Q, Hu J, Mei M, Luo S, Liao K, Zhang Y, He Y, He Y, Xiao**
207 **M, Peng B, Goswami R, Zhao C, Feng Z, Li R, Deng H, Liu C, Zhou B, Ren**
208 **W, Long J, Gong L, Peng C, Gao R, Xiao X.** A combination of captopril
209 challenge test after saline infusion test improves diagnostic accuracy for primary
210 aldosteronism. *Clin. Endocrinol. (Oxf).* 2020;92(2):131–137.
- 211 21. **Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML.** Single dose
212 captopril as a diagnostic test for primary aldosteronism. *J. Clin. Endocrinol.*
213 *Metab.* 1983;57(0021–972; 5):892–896.
- 214 22. **Ma L, Song Y, Mei M, He W, Hu J, Cheng Q, Tang Z, Luo T, Wang Y, Zhen**
215 **Q, Wang Z, Qing H, He Y, Li Q, Yang S.** Age-Related Cutoffs of Plasma
216 Aldosterone/Renin Concentration for Primary Aldosteronism Screening. *Int. J.*
217 *Endocrinol.* 2018;2018. doi:10.1155/2018/8647026.
- 218 23. **Mantero F, Armanini D, Biason A, Boscaro M, Carpena G, Fallo F, Opocher**
219 **G, Rocco S, Scaroni C, Sonino N.** New aspects of mineralocorticoid

- hypertension. *Horm. Res.* 1990;34:175–180.
- 221 24. **Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST.**
222 Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.
223 *Mayo Clin. Proc.* 2001;76(9):877–882.
- 224 25. **Muratani H, Abe I, Tomita Y, Ueno M, Takishita S, Kawazoe N, Tsuchihashi**
225 **T, Kawasaki T, Fujishima M.** Single oral administration of captopril may not
226 bring an improvement in screening of primary aldosteronism. *Clin. Exp.*
227 *Hypertens. A.* 1987;9(2–3):611–614.
- 228 26. **Myśliwiec J, Łukowski Z, Grodzka A, Pilaszewicz A, Drągowski S, Górska**
229 **M.** Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests
230 justified? *J. Renin. Angiotensin. Aldosterone. Syst.* 2012;13(3):367–371.
- 231 27. **Nagano H, Kono T, Saiga A, Kubota Y, Fujimoto M, Felizola SJA, Ishiwata**
232 **K, Tamura A, Higuchi S, Sakuma I, Hashimoto N, Suzuki S, Koide H,**
233 **Takehita N, Sakamoto S, Ban T, Yokote K, Nakamura Y, Ichikawa T, Uno**
234 **T, Tanaka T.** Aldosterone Reduction Rate After Saline Infusion Test May Be a
235 Novel Prediction in Patients With Primary Aldosteronism. *J. Clin. Endocrinol.*
236 *Metab.* 2020;105(3):dgz092.
- 237 28. **Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, Okuno**
238 **H, Shimatsu A, Suzuki T, Naruse M.** Confirmatory Testing in Primary
239 Aldosteronism. *J. Clin. Endocrinol. Metab.* 2012;97(5):1688–1694.
- 240 29. **Naomi S, Umeda T, Iwaoka T, Sato T.** Effects of sodium intake on the captopril
241 test for primary aldosteronism. *Jpn. Heart J.* 1987;28(3):357–365.
- 242 30. **Pilz S, Keppel MH, Trummer C, Theiler-Schwetz V, Pandis M, Borzan V,**
243 **Pittrof M, Obermayer-Pietsch B, Grübler MR, Verheyen N, Stepan V,**
244 **Meinitzer A, Voelkl J, März W, Tomaschitz A.** Diagnostic Accuracy of the
245 Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism. *J.*
246 *Endocr. Soc.* 2019;3(9):1748–1758.
- 247 31. **Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F.** High prevalence
248 of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio
249 as a screening test among Italian hypertensives. *Am. J. Hypertens.* 2002;15(10
250 Pt 1):896–902.
- 251 32. **Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G,**
252 **Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo**
253 **G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero**
254 **F.** Prospective evaluation of the saline infusion test for excluding primary
255 aldosteronism due to aldosterone-producing adenoma. *J. Hypertens.*
256 2007;25:1433–1442.
- 257 33. **Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein**
258 **F, Reincke M.** Confirmatory testing in normokalaemic primary aldosteronism:
259 the value of the saline infusion test and urinary aldosterone metabolites. *Eur. J.*
260 *Endocrinol.* 2006;154(0804–4643; 6):865–873.
- 261 34. **Streeten DHP, Anderson GH.** Simplified screening procedures for primary
262 aldosteronism. Studies on the mechanism of the hyper-responsiveness to
263 furosemide and standing. *Clin. Exp. Hypertens. A.* 1982;4(9–10):1663–1676.

- 264 35. **Sun F, Hong Y, Zhang H, Liu X, Zhao Z, He H, Yan Z, Zhu Z.** Determination
265 of adrenal hypersecretion in primary Aldosteronism without aldosterone-
266 production adenomas. *BMC Endocr. Disord.* 2021;21(1):114.
- 267 36. **Tamura N, Yamada K, Hatakeyama H, Torii-Hanakita M, Kyo C, Kosugi R,**
268 **Yonemoto T, Ogawa T, Kotani M, Usui T, Inoue T.** Parameters of captopril
269 challenge test can predict results of other confirmatory tests for primary
270 aldosteronism and propose the next test to be done. *Endocr. J.* 2020;67(7):741–
271 750.
- 272 37. **Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD,**
273 **Mcwhinney BC, Ungerer JP, Stowasser M.** Diagnosis of Primary
274 Aldosteronism by Seated Saline Suppression Test -Variability Between
275 Immunoassay and HPLC-MS/MS. *J. Clin. Endocrinol. Metab.*
276 2020;105(3):dgz150.
- 277 38. **Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z,**
278 **Cheng Q, Du Z, Wang Z, Ma L, Yang S, Li Q.** Development and Validation of
279 Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism.
280 *J. Clin. Endocrinol. Metab.* 2020;105(7):2449–2456.
- 281 39. **Yamashita K, Yatabe M, Seki Y, Bokuda K, Watanabe D, Shimizu S,**
282 **Morimoto S, Ichihara A.** Comparison of the shortened and standard saline
283 infusion tests for primary aldosteronism diagnostics. *Hypertens. Res.*
284 2020;43(10):1113–1121.
- 285 40. **Zhu KY, Zhang Y, Zhang WJ, Li HY, Feng WH, Zhu DL, Li P.** The captopril
286 challenge test for diagnosing primary Aldosteronism in a Chinese population.
287 *BMC Endocr. Disord.* 2019;19(1):65.
288